Terug
44
Dagbereik
€ 29,22
€ 30,69
52-Weeksbereik
€ 8,64
€ 38,00
Volume
4.058.471
50D / 200D Gem.
€ 33,28
/
€ 26,76
Vorige Slotkoers
€ 29,30
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 17,5 | 0,4 |
| P/B | — | 2,9 |
| ROE % | — | 3,7 |
| Net Margin % | 17,0 | 3,9 |
| Rev Growth 5Y % | 11,9 | 10,0 |
| D/E | — | 0,2 |
Koersdoel Analisten
Hold
€ 43,75
+48.9%
Low: € 36,00
High: € 50,00
Forward K/W
9,4
Forward WPA
€ 3,12
WPA Groei (sch.)
+0,0%
Omzet Sch.
1,2 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 4,15
€ 4,01 – € 4,32
|
1,4 B | 1 |
| FY2029 |
€ 3,84
€ 3,71 – € 4,00
|
1,4 B | 1 |
| FY2028 |
€ 3,81
€ 3,68 – € 3,97
|
1,3 B | 1 |
Belangrijkste Punten
Revenue grew 11,87% annually over 5 years — strong growth
Earnings grew 10400,00% over the past year
Net margin of 16,95% shows strong profitability
Negative free cash flow of -93,00M
PEG of 0,00 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 7,58%
Groei
Revenue Growth (5Y)
11,87%
Revenue (1Y)4,29%
Earnings (1Y)10400,00%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROIC77,67%
Net Margin16,95%
Op. Margin21,15%
Veiligheid
Debt / Equity
N/A
Current Ratio0,71
Interest Coverage5,82
Waardering
P/E Ratio
17,46
P/B RatioN/A
EV/EBITDA14,59
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 4,29% | Revenue Growth (3Y) | 6,47% |
| Earnings Growth (1Y) | 10400,00% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 11,87% | Earnings Growth (5Y) | 0,60% |
| Profitability | |||
| Revenue (TTM) | 1,24B | Net Income (TTM) | 210,00M |
| ROE | N/A | ROA | 17,44% |
| Gross Margin | 80,23% | Operating Margin | 21,15% |
| Net Margin | 16,95% | Free Cash Flow (TTM) | -93,00M |
| ROIC | 77,67% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,71 |
| Interest Coverage | 5,82 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 17,46 | P/B Ratio | N/A |
| P/S Ratio | 2,96 | PEG Ratio | 0,00 |
| EV/EBITDA | 14,59 | Dividend Yield | 0,00% |
| Market Cap | 3,67B | Enterprise Value | 3,82B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1,24B | 1,19B | 1,09B | 901,00M | 791,00M |
| Net Income | 210,00M | 2,00M | -129,00M | -44,00M | 205,00M |
| EPS (Diluted) | 1,64 | 0,02 | 0,01 | -0,37 | 1,31 |
| Gross Profit | 994,00M | 957,00M | 919,00M | 750,00M | 664,00M |
| Operating Income | 262,00M | 32,00M | -156,00M | -81,00M | 213,00M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1,20B | 1,32B | 1,77B | 1,78B | 1,83B |
| Total Liabilities | 1,30B | 1,67B | 1,96B | 1,73B | 1,63B |
| Shareholders' Equity | -98,00M | -348,00M | -191,00M | 51,28M | 203,00M |
| Total Debt | 351,00M | 375,00M | 283,00M | 277,00M | 286,00M |
| Cash & Equivalents | 195,00M | 319,00M | 316,00M | 778,18M | 1,10B |
| Current Assets | 652,00M | 839,00M | 1,27B | 1,27B | 1,44B |
| Current Liabilities | 914,00M | 939,00M | 1,29B | 1,02B | 804,00M |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Growth + Value
Growth at a Reasonable Price (Peter Lynch)
#209 of 326
Recente Activiteit
Ingestapt
Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026